The TeloTest assay utilizes quantitative polymerase chain assay, also called qPCR, and is the most clinically validated technology used to determine telomere length. "The body of scientific and clinical evidence using qPCR is enormous," said Blackburn. "It is really the technology for which all others should be compared since such studies using this technology conclusively support that negative changes in telomere length is directly associated to aging and disease risk."
Envisaged as being taken annually, the test serves as a "check engine" light that may provide an early warning to individuals and their physicians that further medical assessment or changes in lifestyle habits are warranted.
About Telome Health, Inc.
Telome Health, Inc. is a privately held biotechnology company that is focused on developing proprietary telomere based technologies to diagnose, prevent and treat human disease. Its first product, the TeloTest is anticipated to launch in 2012. The company was co-founded by Elizabeth Blackburn who was awarded the Nobel Prize in Medicine for her scientific contributions in the field of telomere biology and Drs. Calvin Harley, Elissa Epel and Jue Li who are internationally recognized experts in this field. The company is located in Menlo Park, CA.
VP of Corporate Development and Strategy
Telome Health, Inc.
|SOURCE Telome Health, Inc.|
Copyright©2010 PR Newswire.
All rights reserved